Effects Of Dapagliflozin On Calcium And Phosphorus Metabolism And Bone Density In Patients With Type 2 Diabete

objectives: In this study,the effects of Dapagliflozin on calcium,phosphorus,bone mineral density,BMI,body weight,waist-to-hip ratio,fasting blood glucose,glycosylated hemoglobin,and blood lipid in patients with type 2 diabetes mellitus(T2DM)before and after Dapagliflozin treatment were analyzed to further assess the benefits and risks of Dapagliflozin treatment and better guide the clinical use of Dapagliflozin.methods: A total of 87 patients with type 2 diabetes who met the "diagnostic criteria established by the American Diabetes Association" were enrolled in the outpatient and ward of the endocrinology Department of Inner Mongolia Forestry General Hospital from September2021 to January 2022.On the basis of the original treatment regimen,Dapagliflozin was added to the treatment for 52 weeks,and the general data,calcium,phosphorus,bone density,BMI,body weight,waist-hip ratio,fasting blood glucose,glycated hemoglobin,blood lipid,uric acid and other indicators of the 87 patients before and after treatment were statistically analyzed.Results:1.After 52 weeks of treatment with Dapagliflozin,the calcium(mol/L)was 2.14(2.31,2.57),2.36(2.3,2.46),respectively;Phosphorus(mol/L)was 1.34(1.19,1.5)and 1.34(1.19,1.45),The difference was not statistically significant(P>0.05).2.BMD(g/cm2)of left femoral neck(0.97±0.09,0.96±0.10)after treatment with Dapagliflozin.52 weeks before and 52 weeks after treatment;Right femoral neck BMD(g/cm2)(0.93±0.10,0.93±0.10);Lumbar BMD(g/cm2)(1.10±0.08,0.96±0.0.08)The difference was not statistically significant(P>0.05).3.The changes of BMI,body weight and waist-to-hip ratio were significantly decreased from 26.62±3.64 to 25.65±3.54 after treatment with Dapagliflozin.52 weeks before and 52 weeks after treatment(P<0.001).The body weight decreased from 76.25±12.19 to 73.44±12.19 with statistical significance(P<0.001).Waist-to-hip ratio decreased from 0.94±0.15 to 0.91±0.12 with statistical significance(P<0.001).4.The changes of fasting blood glucose(FPG)and Hb Alc(8.44±0.69 to 7.19±0.63)and Hb Alc(8.37±0.62 to 7.13±0.64)were statistically significant after treatment with Dapagliflozin.52 weeks before and 52 weeks after treatment(p<0.001).5.Changes in blood lipids,cholesterol(TC)(4.79±0.65,4.74±0.62),triglyceride(TG)(2.07±0.47,1.78±0.36),high density lipoprotein(HLD)(1.03±0.13,1.12±0.17),cholesterol(TC)(4.79±0.65,4.74±0.62),cholesterol(TG)(2.07±0.47,1.78±0.36),The difference was statistically significant(p<0.001).There was no significant difference between uric acid and low density lipoprotein before and after treatment(p>0.05).There was one case of ketoacidosis at week 12 and one case of urinary tract infection at week 20 after treatment with Dapagliflozin.conclusion: Before and after treatment with Dapagliflozin,calcium and phosphorus metabolism and bone mineral density in patients with type 2 diabetes were not affected,but BMI,body weight,waist-to-hip ratio,fasting blood glucose,glycosylated hemoglobin,triglyceride and cholesterol were decreased,and high density lipoprotein was increased.The effect on low density lipoprotein was not statistically significant.